TRANSFEROSOME: A RECENT APPROACH FOR TRANSDERMAL DRUG DELIVERY
Novel drug delivery systems are now a day is creating a new interest in development of drug deliveries. The transdermal route of drug delivery has gained great interest of pharmaceutical research, as it circumvents number of problems associated with oral route of drug administration. Transferosomes are capable of transdermal delivery of low as well as high molecular weight drugs. This offers several potential advantages over conventional routes like avoidance of first pass metabolism, predictable and extended duration of activity, minimizing undesirable side effects, utility of short half life drugs, improving physiological and pharmacological response and have been applied to increases the efficiency of the material transfer across the intact skin, by the use of penetration enhancers and non-ionic surfactant vesicles. It is suitable for controlled and targeted drug delivery and it can accommodate drug molecules with wide range of solubility. Due to its high deformability it gives better penetration of intact vesicles. Transferosome possess an infrastructure consisting of hydrophobic and hydrophilic moieties together and as a result can accommodate drug molecules with wide range of solubility. They are biocompatible and biodegradable as they are made from natural phospholipids and have high entrapment efficiency. In this review, we have focused on transferosome with discussions on novel drug delivery systems for targeted delivery of therapeutics and important issues and challenges for future clinical applications.
Keywords: Novel drug delivery systems, Transferosomes, Transdermal drug delivery, Targeted drug delivery
2. El-Maghraby GM, Williams AC. Vesicular systems for delivering conventional small organic molecules and larger macromolecules to and through human skin. Expert Opin Drug Deliv 2009; 149-163.
3. Walve JR, Bakliwal SR, Rane BR, Pawar SP. Transferosomes: A surrogated carrier for transdermal drug delivery system. Int J App Bio Pharm Tech. 2011; 2 (1):201-214.
4. Kumar A, Pathak K, Bali V. Ultra-adaptable nanovesicular systems: a carrier for systemic delivery of therapeutic agents. Piroxicam Discovery Today 2012; 17(21- 22):1233-41
5. Bain KR., Hadgkraft AJ, James WJ, and Water KA: Prediction of percutaneous penetration STS Publishing, Cardiff 1993; 3b:226-234.
6. Cevc G, Blume G, Sehatzlein A, Gebauer D and Paul A: The skin- a pathway for systemic treatment with patches and lipid-based agent carriers Advance Drug Delivery Reviews 1996; 18:349- 378
7. Jain S., Jain P. Transferosomes: A novel vesicular carrier for enhanced transdermal delivery: development, characterization and performance evaluation, Drug Dev. Ind. Pharm. 2003; 29:1013-1026
8. Paul A., Cevc G., Bachhawat B.K. Transdermal immunization with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transferosomes, Vaccine. 1998; 16 (2-3):188-195.
9. Jain NK. Advances in Controlled and Novel Drug Delivery. CBS Publishers and Distributers First edition. New Delhi. 2001; 426-451.
10. Fry DW, White JC and Goldman ID: Rapid separation of low molecular weight solutes from liposomes without dilution, Journal of Analytical Biochemistry 1978; 90:809-815.
11. Touitou E., Godin B., Dayan N., Weiss C. Intracellular Delivery Mediated By An Ethosomal Carrier. Biomaterials. 2001; 22:3053-3059.
12. Gregor C, Dieter G, Juliane S, Andreas S, Gabriele B, “Ultra-flexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin”, Biophysica Acta, 1998, 1368:201-215.
13. Cevc G, “Isothermal lipid phase”, Transitions Chemistry and Physics of Lipids, 1991, 57:293- 299.
14. Maghraby EI, Williams GM, Barry BW, “Skin delivery of oestradiol from lipid vesicles: importance of liposome structure”, Int. J. Pharma, 2000, 204 (1-2):159-69.
15. Trotta M, Peira E, Carlotti ME, Gallarate M, “Deformable liposomes for dermal administration of methotrexate”, Int. J. Pharma, 2004, 270:119.
16. Hafer C, Goble R, Deering P, Lehmer A, Breut J, “Formulation of interleukin-2 and interferon-alpha containing ultra-deformable carriers for potential transdermal application”, Anticancer Res., 1999, 19 (2c), 1505-7.
17. Modi CD, Bharadia PD, “Transfersomes: New Dominants for Transdermal Drug Delivery”, Am. J. PharmTech Res., 2012, 2 (3):71-91.
18. Benson HA, “Transfersomes for transdermal drug delivery”, Expert Opin. Drug Deliv., 2006, 3 (6):727-37.
19. Dubey V, Mishra D, Asthana A, Jain NK, “Transdermal delivery of a pineal hormone: melatonin via elastic liposomes”, Biomaterials, 2006, 27 (18):3491-6.
20. Cevc G, Blume G., Schatzlein A: Transfersomes-mediated transepidermal delivery improves the regiospecificity and biological activity of corticosteroids in vivo. Journal of Controlled Release 1997; 45:211- 226.
21. Wang XR, Gao SQ, Niu XQ, Li LJ, Ying XY, Hu ZJ, Gao JQ. Capsaicin-loaded nanolipoidal carriers for topical application: design, characterization, and in vitro/ in vivo evaluation. International Journal of Nanomedicine 2017; 12:3881–3898.
22. Kombath RV, Minumula SK, Sockalingam A, Subadhra S, Parre S, Reddy TR, David B, “Critical issues related to transfersomes – novel Vesicular system”, Acta Sci. Pol., Technol. Aliment., 2012, 11 (1), 67-82.
23. Cho YW and Flynn M. Oral delivery of Insulin Wletterx, Lancet, 1989; 23-30: 1518–1519.
24. Wang PY. Implantable Reservoir for Supplemental Insulin Delivery on Demand by External Compression, Biomaterials, 1989; 10: 197–201.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).